Previous investigations of a Li ± Fraumeni like family (Barnes et al., 1992) demonstrated that both the proband and her mother had elevated p53 protein levels in both tumour tissue and normal tissue at sites distant from the tumour, although no mutation was found in the p53 gene. In the present study two recently described functional assays for p53, an apoptotic assay and the functional assay for the separation of alleles in yeast (FASAY), have been employed to study the functional activity of p53 from this patient. The results of the apoptotic assay demonstrated that this patient had a p53 functional defect and the FASAY result suggested that this defect was in fact a germline mutation of the p53 gene. A point mutation of codon 337, which results in an amino acid substitution of a cysteine for an arginine, was demonstrated initially in cDNA and was con®rmed by sequencing of genomic DNA. This is an unusual mutation as it is in the oligomerisation domain of p53, in contrast to the majority of p53 mutations which are in the core DNA binding domain. This mutation results in a protein which still retains partial transactivational activity in the FASAY. The mutation of codon 337 is only the second reported case of a germline missense mutation occurring in the oligomerisation domain of p53.
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The tumour suppressor gene, p53, was ®rst discovered in 1979 (Lane and Crawford, 1979; Linzer and Levine, 1979) . p53 is a 393 amino acid nuclear phosphoprotein which plays a central role in the cellular processes involved in the response to DNA damage (reviewed Kastan et al., 1995) . It is made up of at least four domains, a transactivation domain, a central DNA binding domain, an oligomerisation domain and a regulatory domain, the latter two residing at the carboxy end of the protein.
Following initial studies by Malkin et al. (1990) it is now established that germline p53 mutations are associated with Li ± Fraumeni syndrome (LFS), a dominantly inherited syndrome ®rst proposed by Fraumeni in 1969 (Li and Fraumeni, 1969) . However mutations in the coding region of p53 have only been con®rmed in about 50% of families with LFS (Birch et al., 1994) . Families with this syndrome exhibit multiple primary neoplasms in childhood and early adulthood and the spectrum of cancers which commonly occurs in LFS families includes brain tumours, breast tumours, sarcomas, leukaemia and adrenal cortical tumours (Li et al., 1988) . Families have now been recognised in which there is a similar spectrum of malignancies to LFS but the families do not ®t exactly into the criteria of LFS. These families have been named Li ± Fraumeni like (LFL) (Birch et al., 1994) and p53 germline mutations have been found in 7 ± 20% of these families (Eeles, 1995; Varley et al. manuscript in preparation) . The patient who is the subject of this study is a member of a LFL family and meets the criteria for LFL families as set out by Birch et al. (1994) .
In 1992 Barnes et al. described a member of a LFL family who had elevated levels of p53 protein in the malignant cells of a breast carcinoma and also in normal tissues surrounding the tumour and at sites distant from the tumour. In addition, this patient had high levels of MDM2 protein in normal tissues (Picksley et al., 1996) . Positive staining for p53 was also observed in a breast carcinoma and normal tissues of the proband's mother. The p53 protein from the proband of this LFL family could not be precipitated by the PAb240 antibody, which is speci®c for p53 protein in the mutant conformation, suggesting that the p53 protein was wild-type. Sequencing of the whole cDNA of p53 from the proband failed to demonstrate a mutation in the coding region of the p53 gene.
The investigations by Barnes et al. (1992) concluded that p53 appeared to be wild-type in sequence but these studies did not address the function of the p53 protein.
Two assays have recently been described which can determine if p53 protein is functionally active. One of these assays relies on the induction of apoptosis following g-irradiation in peripheral blood lymphocytes (PBL) (Camplejohn et al., 1995) . The other functional assay, the FASAY, was described by Flaman et al. (1995) and makes use of the transcriptional transactivation property of p53. These two functional assays were employed to determine if the p53 from the LFL family member described previously (Barnes et al., 1992) was functionally active, in an attempt to elucidate the defect in this family.
It is now understood that one of the important functions of p53 is to induce apoptosis following DNA damage, although the mechanism of this induction is not fully known (reviewed by Bates and Vousden, 1996 have an intermediate apoptotic response when treated with ionising radiation or etoposide. Similarly it has been shown that unstimulated PBL of patients with a germline defect in p53 have a reduced apoptotic response following 4 Gy irradiation compared to PBL from normal individuals (Camplejohn et al., 1995) .
In the present study the apoptotic assay was performed on PBL isolated from normal individuals, Li ± Fraumeni family members with known p53 defects and patient 904005 (the patient described by Barnes et al., 1992) . The dierence in the percentage of apoptotic cells of irradiated and unirradiated samples varied between 37% and 55% for normal individuals. The apoptotic response was very much reduced for three Li ± Fraumeni family members (from three dierent Li ± Fraumeni families) with known p53 defects ( Table   a  b c d e f Figure 1 The apoptotic response of PBL was measured as described previously by Camplejohn et al. (1995) . PBL were cultured for 72 h, irradiated with 4 Gy and ®xed 24 h after irradiation. The apoptotic response was then determined, represented by the dierence in the percentage of cells in the sub-G 1 peak on a DNA histogram before and after 4 Gy radiation. (a and b) individual 95006, normal control. (c and d) individual 904006, Li ± Fraumeni patient with a known p53 mutation. (e and f) individual 904005, the member of the Li ± Fraumeni like family under investigation p53 codon 337 mutation in a LFL family ME Lomax et al 1 and Figure 1 ). PBL from patient 904005 were irradiated with 4 Gy and had an increase of apoptotic cells from 1% in unirradiated cells to 2% in irradiated cells (Table 3 and Figure 1 ). This apoptotic response is very much reduced compared to normal individuals and points strongly to a p53-related germline defect, however defects in the pathway upstream or downstream of p53 cannot be ruled out by this assay.
Another and probably related function of p53 is to act as a transcription factor. p53 binds to a consensus sequence in the promoter region of its target gene by its core sequence speci®c DNA binding domain. Mutations in the DNA binding domain of the p53 gene account for the majority of all known mutations (Cho et al., 1994) . A p53 consensus binding sequence has been located in the RGC gene (Kern et al., 1991) and it is this sequence which is utilised in the FASAY test. Transactivation from this consensus sequence produces white yeast colonies in this assay, whereas a failure of transactivation leads to red yeast colonies.
The FASAY test was performed on cDNA derived from PBL and lymphoblastoid cell lines (LCL) of patient 904005, PBL and LCL of normal individuals, PBL of Li ± Fraumeni family members with known p53 mutations and plasmids containing either wild-type p53 or known mutants of p53. Yeast cells were also transformed with linearised vector pRDI22 alone and circular plasmid containing either wild-type or no p53 as further controls. At least 150 yeast colonies were counted for every sample, with the exception of 904001 (134 colonies were counted).
Transformation of linear vector alone always gave less than 10 red colonies, due to self-ligated vector. Transformation of circular plasmid with WT p53 gave only white colonies and circular plasmid with no p53 gene gave only red colonies. Less than 10% red colonies were produced for all cDNAs transformed into yeast from PBL and LCL of normal individuals (Table 2 and Figure 2 ) and from p53 PCR ampli®ed from plasmid containing WT p53. Plasmids with known mutations (273His, 138Val, 285Lys) gave 100% red colonies when they were transformed into yeast (data not shown). cDNA of two individuals from dierent Li ± Fraumeni families in which the p53 mutation was known was transformed into yeast; one individual, 904001, gave 56.0% red colonies and another, 904006, gave 52.9% red colonies (Table 2 and Figure 2 ). All these control samples demonstrate that the FASAY test correctly distinguishes mutant p53 from WT p53.
cDNA from PBL of patient 904005 gave 6.7% red colonies, 53.3% pink colonies and 40% white colonies. This result was repeated with cDNA from LCL (389) of this patient, which gave 8.0% red colonies, 40.9% pink and 51.1% white colonies (Table 3 and Figure 2 ). Similar results were obtained from several transformations of independently prepared cDNA from these two sources. These results suggested that the p53 defect in patient 904005 was a p53 gene mutation as the ratio of white to non-white colonies was typical of individuals heterozygous for p53 mutations.
When the plasmid DNA was recovered from the pink, red and white colonies of patient 904005 and the p53 gene was PCR ampli®ed and re-transformed into yeast, colonies of the same colour grew, e.g. DNA from pink colonies gave 100% pink colonies. The colonies maintained their colour when grown at a lower temperature, therefore, in this case, the pink colour could not be explained by temperature sensitivity as previously described (Flaman et al., 1995) .
Sequencing of the p53 gene from plasmid DNA recovered from multiple yeast colonies showed that patient 904005 had a missense mutation in the p53 gene at codon 337 of exon 10 (Figure 3 ). Codon 337 lies in the oligomerisation domain of the p53 protein, which spans amino acids 323 to 355 (Wang et al., 1994) . This change was predicted to substitute a cysteine for an arginine residue (CGC to TGC; Arg to Cys). The mutation was con®rmed by sequencing exon 10 of genomic DNA (as described by Varley et al., 1995) from a ®broblast cell line, PBL and LCL of this patient. Sequencing of genomic DNA from LCL and PBL con®rmed that patient 904005 was heterozygous for this mutation, although a primary ®broblast cell line demonstrated loss of heterozygosity at this allele. A survey of a database of p53 mutations found in sporadic cancers (Hollstein et al., 1996) revealed that this mutation has been described once before in a Bcell lymphocytic leukaemia (BC-LL). It is likely that the mutation at codon 337 will in¯uence the function of the p53 protein as cells from the patient carrying this mutated protein have demonstrated abnormal responses in two functional assays for p53. We have no clear explanation why a previous study (Barnes et al., 1992) missed this mutation.
The FASAY test was performed on p53 ampli®ed by PCR from the plasmid T7-7Hup53(337C), a plasmid in which the 337 Arg to Cys mutation was generated by site-directed mutagenesis (Transformer Site-Directed Mutagenesis kit and protocol supplied by Clontech, Palo Alto, USA). 97.1% pink colonies and 2.9% red colonies were obtained, con®rming that the mutation in patient 904005 did give pink colonies when assayed in the FASAY test.
The colonies formed in the FASAY from PCR ampli®ed p53 of patient 904005 are red, pink and white. The intermediate colour, pink, is not due to temperature sensitivity; this`pinkness' suggests that not Apoptotic response is the dierence in the percentage of cells in the sub-G 1 peak before and after 4 Gy radiation p53 codon 337 mutation in a LFL family ME Lomax et al all of the p53 activity is abolished in the yeast system but a partial p53 activity remains resulting in some transactivation of the ADE2 gene and therefore some adenine production. One possibility for this partial activity could be that the mutation in this patient leads to the formation of p53 dimers, which can bind DNA but less eciently than tetrameric p53 (Hainaut et al., 1994) . One other LFS family has been described in a b c d Figure 2 Examples of yeast colonies obtained from FASAY. The FASAY was performed on PBL and LCL as described by Flaman et al. (1995) . Vector pSS16 was replaced by vector pRDI22. pRDI22 is identical to pSS16 with the exception that it lacks the URA 3 gene insert, which has the advantage of not requiring gel puri®cation after linearisation. mRNA was isolated from PHA stimulated PBL or from LCL and used as a template for reverse transcription. PCR ampli®ed p53 cDNA and gapped pRDI22 were co-transfected into the yeast cells. p53 codon 337 mutation in a LFL family ME Lomax et al which there is a p53 missense mutation in the oligomerisation domain (Varley et al., 1996) . Transformation of p53 ampli®ed by PCR from tumour tissue of the individual with the Pro 344 mutation, described by Varley et al. (1996) , gave only red and white colonies in the FASAY (data not shown). Therefore the pink colour seen with patient 904005 is not a general feature of p53 mutations occurring in the oligomerisation domain. Many investigators concentrate on exons 4 to 9 when looking for mutations as this is where the majority of known mutations lie. However, the apparent preponderance of mutations in this central region of p53 may be exaggerated by the fact that many studies only examine this region. The apoptotic assay should detect any changes which cause loss of p53 function and the FASAY is able to pick up mutations from exon 4 (codon 67) to exon 10 (codon 347) in the p53 gene. Whilst the majority of lesions do occur within this region, even this assay will miss some mutations. For example, Varley and colleagues have found a LFS family with a mutation in exon 1 (personal communication). The results of Varley et al. (1996) and this study demonstrate the importance of looking for mutations along the whole gene as these two studies have shown that point mutations in the oligomerisation domain of p53 can be functionally disruptive.
In summary, with the use of two functional assays this study has demonstrated that a member of a Li ± Fraumeni like family has an unusual mutation in the p53 gene. This mutation is in the oligomerisation domain of p53 and there is a strong possibility that it disrupts the formation of p53 tetramers required for ecient DNA binding. The application of functional assays to detect p53 defects is extremely valuable in such studies. These assays are reliable, rapid and distinguish between functionally disruptive and silent mutations. In combination with more traditional methods, such as direct sequencing, it is possible for functional assays, such as the apoptotic assay and FASAY, to detect a wide spectrum of p53-related defects with the minimum time and eort. These features are important if large numbers of LFS or LFL family members are to be screened for p53 mutations. Clinical Genetics, Guy's Hospital, London). ME Lomaz was supported by the Association for International Cancer Research.
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C GC (Arg) to TGC (Cys) substitution at codon 337 Figure 3 p53 gene mutation sequence of cDNA recovered from a pink yeast colony. Plasmid DNA was recovered from yeast by standard molecular biology techniques and 5 mg was sequenced with a Sequenase Version 2.0 kit (USB, Cleveland, USA), according to manufacturer's instructions. The oligonucleotides used for DNA sequencing are available on request. Arrow points to C to T substitution codon 337 aa 337 R to C aa 337 R to C ND: not determined. Individual 904005 is the member of a Li ± fraumeni like family under investigation. 389 are LCL derived from the PBL of patient 904005. T7-7Hup53(337C) is a plasmid containing p53 in which the mutation of patient 904005 has been generated by site-directed mutagenesis. Apoptotic response is the dierence in the percentage of cells in the sub-G 1 peak before and after 4 Gy radiation
